Literature DB >> 7530240

Expression of CD44 variant isoforms in normal and neoplastic cells of the lung.

O Washimi1, R Ueda, Y Ariyoshi, M Suyama, T Seki, T Takahashi, T Takahashi.   

Abstract

CD44 is a cell surface receptor that has been implicated in lymphocyte homing, hematopoiesis, cell migration and possibly also tumor metastasis. In the present study, expression of CD44 variant (CD44v) isoforms was analyzed in 23 lung cancer specimens together with corresponding normal lung tissues by Southern blot analysis coupled with reverse transcription-polymerase chain reaction amplification. We found that CD44v isoforms were expressed in all lung cancer specimens, suggesting a possible role in the establishment of metastases by these highly malignant tumors, but normal tissues were also positive. This is in marked contrast to the previous reports of essentially negligible expression of CD44v isoforms in normal colon and breast, and suggests a physiological function in the lung.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530240      PMCID: PMC5919360          DOI: 10.1111/j.1349-7006.1994.tb02915.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  24 in total

Review 1.  Integrins.

Authors:  E Ruoslahti
Journal:  J Clin Invest       Date:  1991-01       Impact factor: 14.808

2.  Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells.

Authors:  W G Carter; E A Wayner
Journal:  J Biol Chem       Date:  1988-03-25       Impact factor: 5.157

3.  Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.

Authors:  S Reber; S Matzku; U Günthert; H Ponta; P Herrlich; M Zöller
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

4.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

5.  Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.

Authors:  K K Tanabe; L M Ellis; H Saya
Journal:  Lancet       Date:  1993-03-20       Impact factor: 79.321

6.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.

Authors:  T Takahashi; T Takahashi; H Suzuki; T Hida; Y Sekido; Y Ariyoshi; R Ueda
Journal:  Oncogene       Date:  1991-10       Impact factor: 9.867

7.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

9.  The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.

Authors:  I Stamenkovic; A Aruffo; M Amiot; B Seed
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

10.  Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition.

Authors:  K Miyake; C B Underhill; J Lesley; P W Kincade
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  3 in total

Review 1.  CD44 in inflammation and metastasis.

Authors:  J Lesley; R Hyman; N English; J B Catterall; G A Turner
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

2.  CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma.

Authors:  N Guriec; L Marcellin; B Gairard; H Caldéroli; A Wilk; R Renaud; J P Bergerat; F Oberling
Journal:  Clin Exp Metastasis       Date:  1996-10       Impact factor: 5.150

3.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.